These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 26200113)

  • 1. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
    Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
    J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
    Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
    Giddens JP; Wang LX
    Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans.
    Tsukimura W; Kurogochi M; Mori M; Osumi K; Matsuda A; Takegawa K; Furukawa K; Shirai T
    Biosci Biotechnol Biochem; 2017 Dec; 81(12):2353-2359. PubMed ID: 29090617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins.
    Yang Q; Wang LX
    Methods Enzymol; 2017; 597():265-281. PubMed ID: 28935106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
    Popp O; Moser S; Zielonka J; Rüger P; Hansen S; Plöttner O
    MAbs; 2018; 10(2):290-303. PubMed ID: 29173063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.
    Liu CP; Tsai TI; Cheng T; Shivatare VS; Wu CY; Wu CY; Wong CH
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):720-725. PubMed ID: 29311294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
    Raju TS
    Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.
    Zou G; Ochiai H; Huang W; Yang Q; Li C; Wang LX
    J Am Chem Soc; 2011 Nov; 133(46):18975-91. PubMed ID: 22004528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.
    Yu M; Brown D; Reed C; Chung S; Lutman J; Stefanich E; Wong A; Stephan JP; Bayer R
    MAbs; 2012; 4(4):475-87. PubMed ID: 22699308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
    Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
    Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
    Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
    J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.